Publication list (selected)
1. Ogura T, Azuma K, Takeiwa T, Sato J, Kinowaki K, Ikeda K, Kawabata H, Inoue S:
TRIM39 is a poor prognostic factor for patients with estrogen receptor‐positive breast
cancer and promotes cell cycle progression. Pathol Int 72, 96-106, 2022.
2. Kamada S, Takeiwa T, Ikeda K, Horie K and Inoue S: Emerging roles of COX7RP andmitochondrial oxidative phosphorylation in breast cancer. Front Cell Dev Biol 10,717881, 2022.
3. Azuma K, Osuka Y, Kojima N, Sasai H, Kim H, Inoue S: Association of vitamin K
insufficiency with cognitive dysfunction in community-dwelling older adults. Front
Nutri 8, 811831, 2022.
4. Nagasawa S, Ikeda K, Shintani D, Yang C, Takeda S, Hasegawa K, Horie K, Inoue S:
Identification of a novel oncogenic fusion gene SPON1-TRIM29 in clinical ovariancancer that promotes cell and tumor growth and enhances chemoresistance in A2780 cells.
Int J Mol Sci 23, 689, 2022.
5. Kamada S, Ikeda K, Suzuki T, Sato W, Kitayama S, Kawakami S, Ichikawa T, Horie K,
Inoue S: Clinicopathological and preclinical patient-derived model studies define highexpression of NRN1 as a diagnostic and therapeutic target for clear cell renal cell
carcinoma. Front Oncol 11, 758503, 2021.

6. Ogura T, Azuma K, Sato J, Kinowaki K, Takayama KI, Takeiwa T, Kawabata H, Inoue S:
OCT1 is a poor prognostic factor for breast cancer patients and promotes cell proliferation
via inducing NCAPH. Int J Mol Sci 22, 11505, 2021.
7. Takeiwa T, Mitobe Y, Ikeda K, Hasegawa K, Horie K, Inoue S: Long intergenic
noncoding RNA OIN1 promotes ovarian cancer growth by modulating apoptosis-related
gene expression. Int J Mol Sci 22, 11242, 2021.
8. Takamatsu K, Tanaka J, Katada R, Azuma K, Takakura I, Aota K, Kamatani T, Shirota T,
Inoue S, Mishima K: Aging-associated stem/progenitor cell dysfunction in the salivary
glands of mice. Exp Cell Res 409, 112889, 2021.
9. Sato K, Takayama K, Hashimoto M, Inoue S: Transcriptional and post-transcriptional
regulations of amyloid-β precursor protein, APP. Front Aging 2, 721579, 2021.
10. Azuma K, Ikeda K, Suzuki T, Aogi K, Horie-Inoue K, Inoue S: TRIM47 activates NF-κB
signaling via PKCε/PKD3 stabilization and contributes to endocrine therapy resistance inbreast cancer. Proc Natl Acad Sci U S A 118, e2100784118, 2021.
11. Takayama K, Kosaka T, Suzuki T, Hongo H, Oya M, Fujimura T, Suzuki Y, Inoue S:
Subtype-specific collaborative transcription factor networks are promoted by OCT4 in
the progression of prostate cancer. Nat Commun 12, 3766, 2021.
12. Takayama K, Honma T, Suzuki T, Kondoh Y, Osada H, Suzuki Y, Yoshida M, Inoue S:

Targeting epigenetic and post-transcriptional gene regulation by PSF impairs hormone
therapy-refractory cancer growth. Cancer Res 81, 3495-3508, 2021.
13. Kamada S, Namekawa T, Ikeda K, Suzuki T, Kagawa M, Takeshita H, Yano A, Okamoto
K, Ichikawa T, Horie-Inoue K, Kawakami S, Inoue S: Functional inhibition of cancer
stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell
carcinoma. Oncogene 40, 3899-3913, 2021.
14. Takeiwa T, Ikeda K, Horie-Inoue K, Inoue S: Mechanisms of apoptosis-related long noncoding RNAs in ovarian cancer. Front Cell Dev Biol 9, 641963, 2021.
15. Hashimoto M, Ho G, Sugama S, Takenouchi T, Waragai M, Inoue S, Masliah E: Possible
role of activin in the adiponectin paradox-induced progress of Alzheimer’s disease. J
Alzheimers Dis 81, 451-458, 2021.
16. Yang C, Ikeda K, Horie-Inoue K, Sato W, Hasegawa K, Takeda S, Itakura A, Inoue S:
Transcriptomic analysis of hormone-sensitive patient-derived endometrial cancer
spheroid culture defines Efp as a proliferation modulator. Biochem Biophys Res
Commun 548, 204-210, 2021.
17. Shiba S, Ikeda K, Horie-Inoue K, Azuma K, Hasegawa T, Amizuka N, Tanaka T, Takeiwa
T, Shibata Y, Koji T, Inoue S: Vitamin K-dependent γ-glutamyl carboxylase in Sertoli

cells is essential for male fertility in mice. Mol Cell Biol MCB.00404-20, 2021 andHighlighted in “Spotlights” and Cover.
18. Murayama T, Takauchi Y, Yamawaki K, Natsume T, Li M, Nichole R Chaverra,
Nishimura T, Kogure Y, Nakata A, Tominaga K, Sasahara A, Yano M, Ishikawa S, Ohta
T, Ikeda K, Horie-Inoue K, Inoue S, Seki M, Suzuki Y A, Sugano S, Enomoto T, Tanabe
M, Tada K, Kanemaki M, Okamoto K, Tojo A, Gotoh N: MCM10 compensates for Mycinduced DNA replication stress in breast cancer stem-like cells. Cancer Sci 112, 12091224, 2021.
19. Takamatsu Y, Hob G, Wada R, Inoue S, Hashimoto M: Adiponectin paradox as atherapeutic target of the cancer evolvability in aging. Neoplasia 23, 112-117, 2021.
20. Sato J, Azuma K, Kinowaki K, Ikeda K, Ogura T, Takazawa Y, Kawabata H, Kitagawa
M, Inoue S: Combined A20 and tripartite motif-containing 44 as poor prognostic factors
for breast cancer patients of the Japanese population. Pathol Int 71, 60-69, 2021.
21. Sato J, Azuma K, Kinowaki K, Ikeda K, Ogura T, Takazawa Y, Kawabata H, Kitagawa
M, Inoue S: Combined use of immunoreactivities of RIG-I with Efp/TRIM25 forpredicting prognosis of estrogen receptor-positive breast cancer patients. Clin Breast
Cancer S1526-8209(20)30328-1, 2020.

22. Takayama K, Fujimura T, Suzuki Y, Inoue S: Identification of long non-coding RNAs in
advanced prostate cancer associated with androgen receptor splicing factors. Commun
Biol 3, 393, 2020.
23. Namekawa T, Kitayama S, Ikeda K, Horie-Inoue K, Suzuki T, Okamoto K, Ichikawa T,
Yano A, Kawakami S, Inoue S: HIF1α inhibitor 2-methoxyestradiol decreases NRN1
expression and represses in vivo and in vitro growth of patient-derived testicular germ
cell tumor spheroids. Cancer Lett 489, 79-86, 2020.
24. Mitobe Y, Iino K, Takayama KI, Ikeda K, Suzuki T, Aogi K, Kawabata H, Suzuki Y,
Horie-Inoue K, Inoue S: PSF promotes ER-positive breast cancer progression via
posttranscriptional regulation of ESR1 and SCFD2. Cancer Res 80, 2230-2242, 2020.
25. Mitobe Y, Ikeda K, Sato W, Kodama Y, Naito M, Gotoh N, Miyata K, Kataoka K, Sasaki
H, Horie-Inoue K, Inoue S: Proliferation-associated long noncoding RNA, TMPO-AS1,
is a potential therapeutic target for triple-negative breast cancer. Cancer Sci 111, 24402450, 2020.
26. Yang C, Ota-Kurogi N, Ikeda K, Okumura T, Horie-Inoue K, Takeda S, Inoue S:
microRNA-191 regulates endometrial cancer cell growth via TET1-mediated epigenetic
modulation of APC. J Biochem 68, 7-14, 2020.

27. Iino K, Mitobe Y, Ikeda K, Takayama KI, Suzuki T, Kawabata H, Suzuki Y, HorieInoue K, Inoue S: RNA-binding protein NONO promotes breast cancer proliferation by
post-transcriptional regulation of SKP2 and E2F8. Cancer Sci 111, 148-159, 2020.
28. Obinata D, Lawrence MG, Takayama K, Choo N, Risbridger GP, Takahashi S, Inoue S:
Recent discoveries in the androgen receptor pathway in castration-resistant prostatecancer. Front Oncol 10, 581515, 2020.
29. Kamada S, Takeiwa T, Ikeda K, Horie-Inoue K, Inoue S: Long noncoding RNAs
involved in metabolic alterations in breast and prostate cancers. Front Oncol 10,593200, 2020.
30. Kobayashi A, Azuma K, Ikeda K, Inoue S: Mechanisms underlying the regulation of
mitochondrial respiratory chain complexes by nuclear steroid receptors. Int J Mol Sci
21, 6683, 2020.
31. Takeiwa T, Ikeda K, Mitobe Y, Horie-Inoue K, Inoue S: Long noncoding RNAs
involved in the endocrine therapy resistance of breast cancer. Cancers 12, 1424, 2020.
32. Azuma K, Ikeda K, Inoue S: Functional mechanisms of mitochondrial respiratory chain
supercomplex assembly factors and their involvement in muscle quality. Int J Mol Sci
21, 3182, 2020.

33. Takeiwa T, Mitobe Y, Ikeda K, Horie-Inoue K, Inoue S: Roles of splicing factors inhormone-related cancer progression. Int J Mol Sci 21, 1551, 2020.
34. Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, Inoue S: ESR1stabilizing lncRNA TMPO-AS1 promotes hormone-refractory breast cancer
progression. Mol Cell Biol 39, e00261-19, 2019. and Highlighted
in "Spotlight" and Cover.
35. Takayama K, Fujiwara K, Inoue S: Amyloid precursor protein, an androgen-regulated
gene, is targeted by RNA-binding protein PSF/SFPQ in neuronal cells. Genes Cells 24,
719-730, 2019.
36. Ikeda K, Horie-Inoue K, Suzuki T, Hobo R, Nakasato N, Takeda S, Inoue S:
Mitochondrial supercomplex assembly promotes breast and endometrial tumorigenesisby metabolic alterations and enhanced hypoxia tolerance. Nat Commun 10, 4108, 2019.
37. Yamamoto S, Takayama K, Obinata D, Fujiwara K, Ashikari D, Takahashi S, Inoue S:
Identification of new octamer transcription factor 1-target genes upregulated incastration-resistant prostate cancer. Cancer Sci 110, 3476-3485, 2019.
38. Shiba S, Ikeda K, Suzuki T, Shintani D, Okamoto K, Horie-Inoue K, Hasegawa K,
Inoue S: Hormonal regulation of patient-derived endometrial cancer stem-like cells

generated by three-dimensional culture. Endocrinology 160, 1895-1906, 2019 andHighlighted in "eNews", pii: en.2019-00362.
39. Namekawa T, Ikeda K, Horie-Inoue K, Suzuki T, Okamoto K, Ichikawa T, Yano, A,
Kawakami S, Inoue S: ALDH1A1 in patient-derived bladder cancer spheroids activates
retinoic acid signaling leading to TUBB3 overexpression and tumor progression. Int J
Cancer 146, 1099-1113, 2019.
40. Takayama K, Suzuki Y, Yamamoto S, Obinata D, Takahashi S, Inoue S: Integrative
genomic analysis of OCT1 reveals coordinated regulation of androgen receptor inadvanced prostate cancer. Endocrinology 160, 463-472, 2019.
41. Azuma K, Inoue S: Multiple modes of vitamin K actions in aging-related
musculoskeletal disorders. Int J Mol Sci 20, 2844, 2019.
42. Ikeda K, Horie-Inoue K, Inoue S: Functions of estrogen and estrogen receptor signalingon skeletal muscle. J Steroid Biochem Mol Biol 191, 105375, 2019.
43. Namekawa T, Ikeda K, Horie-Inoue K, Inoue S: Application of prostate cancer models
for preclinical study: Advantages and limitations of cell lines, patient-derived
xenografts, and three-dimensional culture of patient-derived cells. Cells 8, 74, 2019.

44. Takayama K, Suzuki T, Fujimura T, Takahashi S, Inoue S: COBLL1 modulates cellmorphology and facilitates androgen receptor genomic binding in advanced prostatecancer. Proc Natl Acad Sci U S A 115, 4975-4980, 2018.
45. Takayama K, Suzuki T, Tanaka T, Fujimura T, Takahashi S, Urano T, Ikeda K, Inoue
S: TRIM25 enhances cell growth and cell survival by modulating p53 signals via
interaction with G3BP2 in prostate cancer. Oncogene 37, 2165-2180, 2018.
46. Takayama K, Suzuki T, Fujimura T, Takahashi S, Inoue S: Association of USP10 with
G3BP2 inhibits p53 signaling and contributes to poor outcome in prostate cancer. Mol
Cancer Res 16, 846-856, 2018.
47. Miyazaki T, Ikeda K, Sato W, Horie-Inoue K, Inoue S: Extracellular vesicle-mediated
EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escapeand tumor progression. Oncogenesis 7, 7, 2018
48. Mitobe Y, Takayama K, Horie-Inoue K, Inoue S: Prostate cancer-associatedlncRNAs. Cancer Lett 418, 159-166, 2018.
49. Takayama K, Suzuki T, Fujimura T, Yamada Y, Takahashi S, Homma Y, Suzuki Y,
Inoue S: Dysregulation of spliceosome gene expression in advanced prostate cancer by
RNA-binding protein PSF. Proc Natl Acad Sci U S A, 114, 10461-10466, 2017.

50. Shiba S, Ikeda K, Horie-Inoue K, Nakayama A, Tanaka T, Inoue S: Deficiency of
COX7RP, a mitochondrial supercomplex assembly promoting factor, lowers blood
glucose level in mice. Sci Rep 7, 7606, 2017.
51. Ashikari D, Takayama K, Tanaka T, Suzuki Y, Obinata D, Fujimura T, Urano T,
Takahashi S, Inoue S: Androgen induces G3BP2 and SUMO-mediated p53 nuclear
export in prostate cancer. Oncogene 36, 6272-6281, 2017.
52. Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, Osaki A, Saeki T,
Horie-Inoue K, Inoue S: TRIM44 is a poor prognostic factor for breast cancer patientsas a modulator of NF-kB signaling. Int. J. Mol. Sci 18, pii: E1931, 2017.
53. Nagai S, Ikeda K, Horie-Inoue K, Shiba S, Nagasawa S, Takeda S, Inoue S: Estrogen
modulates exercise endurance along with mitochondrial uncoupling protein 3
downregulation in skeletal muscle of female mice. Biochem Biophys Res Commun
480, 758-764, 2016.
54. Huang L, Zhang H, Cheng CY, Wen F, Tam POS, Zhao P, Chen H, Li Z, Chen L, Tai
Z, Yamashiro K, Deng S, Zhu X, Chen W, Li C, Lu F, Li Y, Cheung CMG, Shi Y,
Miyake M, Lin Y, Gong B, Liu X, Sim KS, Yang J, Mori K, Zhang X, Cackett PD,
Tsujikawa M, Nishida K, Hao F, Ma S, Lin H, Chen J, Fei P, Lai TYY, Tang S, Laude
A, Inoue S, Yeo IY, Sakurada Y, Zhou Y, Iijima H, Honda S, Lei C, Zhang L, Zheng H,

Jiang D, Zhu X, Wong TY, Khor CC, Pang CP, Yoshimura N, Yang Z: A missense
variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. Nat
Genet 48, 640-647, 2016.
55. Aihara H, Nakagawa T, Mizusaki H, Yoneda M, Kato M, Doiguchi M, Imamura Y,
Higashi M, Ikura T, Hayashi T, Kodama Y, Oki M, Nakayama T, Edwin Cheung,
Aburatani H, Takayama K, Koseki H, Inoue S, Takeshima Y, Ito T: Histone H2A T120
phosphorylation promotes oncogenic transformation via upregulation of cyclin D1. Mol
Cell 64, 176-188, 2016.
56. Misawa A, Takayama K, Urano T, Inoue S: Androgen-induced long noncoding RNA(lncRNA) SOCS2-AS1 promotes cell growth and inhibits apoptosis in prostate Cancer
cells. J Biol Chem 291, 17861-80, 2016.
57. Obinata D, Takayama K, Fujiwara K, Suzuki T, Tsutsumi S, Fukuda N, Nagase H,
Fujimura T, Urano T, Homma Y, Aburatani H, Takahashi S, Inoue S: Targeting Oct1
genomic function inhibits androgen receptor signaling and castration-resistant prostatecancer growth. Oncogene 35, 6350-6358, 2016.
58. Takayama K, Misawa A, Suzuki T, Takagi K, Hayashizaki Y, Fujimura T, Homma Y,
Takahashi S, Urano T, Inoue S: TET2 repression by androgen hormone regulates global

hydroxymethylation status and prostate cancer progression. Nat Commun 6, 8219,
2015.
59. Azuma K, Shiba S, Hasegawa T, Ikeda K, Urano T, Horie-Inoue K, Ouchi Y, Amizuka
N, Inoue S: Osteoblast-specific γ-glutamyl carboxylase-deficient mice display enhancedbone formation with aberrant mineralization. J Bone Miner Res 30, 1245-1254, 2015.
60. Azuma K, Casey SC, Urano T, Horie-Inoue K, Ouchi Y, Blumberg B, Inoue S: Pregnane
X receptor knockout mice display aging-dependent wearing of articular cartilage. PLoS
One 10, e0119177, 2015.
61. Zhang P, Elabd S, Hammer S, Solozobova V, Yan H, Bartel F, Inoue S, Henrich T,
Wittbrodt J, Loosli F, Davidson G, Blattner C: TRIM25 has a dual function in the
p53/Mdm2 circuit. Oncogene 34, 5729-5738, 2015.
62. Urano T, Shiraki M, Sasaki N, Ouchi Y, Inoue S: SLC25A24 as a novel susceptibility
gene for low fat mass in humans and mice. J Clin Endocrinol Metab 100, E655-E663,
2015.
63. Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Takahashi S, Homma Y, Urano T,
Aburatani H, Inoue S: Integrative analysis of FOXP1 function reveals a tumor
suppressive effect in prostate cancer. Mol Endocrinol 28, 2012-2024, 2014.

64. Takayama K, Suzuki T, Fujimura T, Urano T, Takahashi S, Homma Y, Inoue S: CtBP2
modulates the androgen receptor to promote prostate cancer progression. Cancer
Res 74, 6542-6553, 2014.
65. Miyazaki T, Ikeda K, Horie-Inoue K, Kondo T, Takahashi S, Inoue S: EBAG9 modulates
host immune defense against tumor formation and metastasis by regulating cytotoxic
activity of T lymphocytes. Oncogenesis 3, e126, 2014.
66. Urano T, Shiraki M, Sasaki N, Ouchi Y, Inoue S: Large-scale analysis reveals afunctional single-nucleotide polymorphism in the 5'-flanking region of PRDM16 geneassociated with lean body mass. Aging Cell 13, 739-743, 2014.
67. Azuma K, Ouchi Y, Inoue S: Vitamin K: novel molecular mechanisms of action and its
roles in osteoporosis. Geriatr Gerontol Int 14, 1-7, 2014.
68. Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, Ikeda K, Urano T,
Fujimura T, Takagi K, Takahashi S, Homma Y, Ouchi Y, Aburatani H, Hayashizaki Y,
Inoue S: Androgen-responsive long noncoding RNA CTBP1-AS promotes prostatecancer. EMBO J 32, 1665-1680, 2013 and highlighted in "Have you seen?" pp.16531654.

69. Ikeda K, Shiba S, Horie-Inoue K, Shimokata K, Inoue S: A stabilizing factor for
mitochondrial respiratory supercomplex assembly regulates energy metabolism inmuscle. Nat Commun 4, 2147, 2013.
70. Takayama K, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, Takahashi S,
Homma Y, Ouchi Y, Inoue S: TACC2 is an androgen-responsive cell cycle regulator
promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol
Endocrinol 26, 748-761, 2012 and highlighted in "Editorial" p.715.
71. Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D, Horie-Inoue K,
Takahashi S, Ouchi Y, Homma Y, Inoue S: 14-3-3ζ, a novel androgen-responsive gene,is upregulated in prostate cancer and promotes prostate cancer cell proliferation andsurvival. Clin Cancer Res 18, 5617-5627, 2012.
72. Urano T, Shiraki M, Ouchi Y, Inoue S: Association of circulating sclerostin levels with
fat mass and metabolic disease-related markers in Japanese postmenopausal women. J
Clin Endocrinol Metab 97, E1473-E1477, 2012.
73. Urano T, Shiraki M, Yagi H, Ito M, Sasaki N, Sato M, Ouchi Y, Inoue S: GPR98/Gpr98
gene is involved in the regulation of human and mouse bone mineral density. J Clin
Endocrinol Metab 97, E565-E574, 2012.

74. Azuma K, Inoue S: Genomic and non-genomic actions of estrogen: recent
developments. Biomol Concepts. 3, 365-370, 2012.
75. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K, Urano T,
Kawazu C, Hasegawa A, Ikeo K, Gojyobori T, Ouchi Y, Hayashizaki Y, Aburatani H,
Inoue S: Integration of cap analysis of gene expression and chromatin
immunoprecipitation analysis on array reveals genome-wide androgen receptor
signaling in prostate cancer cells. Oncogene 30, 619-630, 2011.
76. Azuma K, Casey SC, Ito M, Urano T, Horie K, Ouchi Y, Kirchner S, Blumberg B, Inoue
S:

Pregnane X receptor knockout mice display osteopenia with reduced bone formationand enhanced bone resorption. J Endocrinol 207, 257-263, 2010.
77. Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, Fujimura T,
Kumagai J, Urano T, Sakaki Y, Shirahige K, Sasano H, Takahashi S, Kitamura T,
Ouchi Y, Aburatani H, Inoue S: Amyloid precursor protein is a primary androgen target
gene that promotes prostate cancer growth. Cancer Res 69, 137-142, 2009.
78. Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y, Inoue S: Associationof estrogen receptor α and histone deacetylase 6 causes rapid deacetylation of tubulin in
breast cancer cell. Cancer Res 69, 2935-2940, 2009.

79. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z,
Inoue S, Jung JU: TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-Imediated antiviral activity. Nature 446, 916-921, 2007.
80. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S: Steroid and xenobiotic
receptor SXR mediates vitamin K2-activated transcription of extracellular matrixrelated genes and collagen accumulation in osteoblastic cells. J Biol Chem 281, 1692716934, 2006, Cover, and highlighted in "Paper of this week".
81. Ogushi T, Takahashi S, Takeuchi T, Urano T, Horie-Inoue K, Kumagai J, Kitamura T,
Ouchi Y, Muramatsu M, Inoue S: Estrogen receptor-binding fragment-associatedantigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer
Res 65, 3700-3706, 2005.
82. Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S,
Lin M, Forman BM, Blumberg B: Vitamin K2 regulation of bone homeostasis is mediatedby the steroid and xenobiotic receptor SXR. J Biol Chem 278, 43919-43927, 2003.
83. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S: Efp
targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature 417, 871875, 2002.

84. Orimo A, Inoue S, Minowa O, Tominaga N, Tomioka Y, Sato M, Kuno J, Hiroi H,
Shimizu Y, Suzuki M, Noda T, Muramatsu M: Underdeveloped uterus and reduced
estrogen responsiveness in mice with disruption of the estrogen-responsive finger
protein gene, which is a direct target of estrogen receptor alpha. Proc Natl Acad Sci U S
A 96, 12027-12032, 1999.
85. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T, Ikegami A, Ouchi Y,
Orimo H, Muramatsu M: Genomic binding-site cloning reveals an estrogen-responsive
gene that encodes a RING finger protein. Proc Natl Acad Sci U S A 90, 11117-11121,
1993.
86. Inoue S, Kondo S, Hashimoto M, Kondo T, Muramatsu M: Isolation of estrogen
receptor-binding sites in human genomic DNA. Nucleic Acids Res 19, 4091-4096,
1991.